Question 1

What is the post-antibiotic effect (PAE)?

Accepted Answer

The post-antibiotic effect (PAE) is the persistent suppression of bacterial growth that continues after antibiotic concentrations fall below the minimum inhibitory concentration (MIC). During exposure to an antibiotic above the MIC, bacteria sustain sub-lethal injury to cell membranes, ribosomes, or DNA synthesis machinery. After drug concentrations fall below the MIC, the damaged bacteria cannot immediately resume growth — the recovery period is the PAE, typically measured as the time (in hours) for a 10-fold (1 log10) increase in bacterial count after drug removal. PAE is an in vitro phenomenon measured experimentally but has direct clinical implications: drugs with long PAEs can be dosed less frequently without losing efficacy, because the period below MIC still suppresses bacterial regrowth.

Question 2

Which antibiotics have a significant post-antibiotic effect?

Accepted Answer

Antibiotics with significant PAEs fall into two groups. Concentration-dependent antibiotics (those that kill more bacteria as concentrations rise above MIC) consistently demonstrate long PAEs: aminoglycosides (gentamicin, tobramycin, amikacin) exhibit PAEs of 2–7 hours against Gram-negative organisms; fluoroquinolones (ciprofloxacin, levofloxacin) have PAEs of 2–6 hours. Time-dependent antibiotics (those that kill bacteria when concentrations are maintained above MIC) typically have short or absent PAEs against Gram-negative bacteria: beta-lactams (penicillins, cephalosporins) have PAEs of 0–2 hours against Gram-negatives. However, beta-lactams and glycopeptides (vancomycin) have longer PAEs against Gram-positive organisms (Staphylococcus aureus, Streptococcus). Azithromycin has a long intracellular PAE due to accumulation in phagocytes — the basis for shorter-course therapy for intracellular pathogens.

Question 3

How does the post-antibiotic effect justify once-daily aminoglycoside dosing?

Accepted Answer

Once-daily (extended-interval) aminoglycoside dosing exploits two pharmacodynamic properties simultaneously: concentration-dependent killing and the post-antibiotic effect. Aminoglycosides are concentration-dependent — the pharmacodynamic target is Cmax/MIC ≥10:1. A once-daily dose of 7 mg/kg achieves a higher Cmax than divided dosing (e.g., 2.5 mg/kg three times daily), maximising the Cmax/MIC ratio and bactericidal killing. After the peak, concentrations fall below MIC — but bacterial regrowth is suppressed for 2–7 hours by the PAE. The daily interval (24 hours) allows a sub-MIC period that coincides with the PAE window, followed by a drug-free period that reduces the concentration-time exposure in renal proximal tubular cells, reducing nephrotoxicity. Additionally, aminoglycoside uptake into renal tubular cells is saturable — during the drug-free period, accumulated aminoglycoside is shed, reducing tubular toxicity compared with continuous exposure.

Question 4

Does the post-antibiotic effect occur in vivo (in patients)?

Accepted Answer

The PAE is primarily defined and measured in vitro in bacterial culture systems. However, an in vivo post-antibiotic effect (also called the post-antibiotic sub-MIC effect — PA-SME) has been demonstrated in animal infection models and is the pharmacokinetic/pharmacodynamic rationale for extended-interval dosing in clinical practice. In vivo, the PAE may be extended beyond the in vitro PAE by several factors: sub-inhibitory concentrations of drug still present in tissues (post-antibiotic sub-MIC effect), leucocyte-mediated killing of PAE-affected bacteria that have reduced virulence and impaired growth, and cytokine-mediated immune enhancement. The PA-SME can add 1–3 additional hours to the growth suppression period in vivo. The clinical correlation between in vitro PAE, in vivo PA-SME, and clinical outcomes has been validated for aminoglycosides in numerous randomised clinical trials demonstrating equivalent clinical efficacy with once-daily dosing versus conventional divided dosing.

Question 5

How does the post-antibiotic effect relate to antibiotic resistance selection?

Accepted Answer

The PAE has an important relationship to resistance prevention. During the post-antibiotic effect period, bacteria are metabolically stressed and growth-suppressed — they are less likely to replicate and express resistance mutations. However, extended sub-MIC periods can increase the probability of selecting pre-existing resistant mutants, because sub-MIC concentrations create selective pressure without achieving bactericidal concentrations. The mutant selection window (MSW) — the concentration range between MIC of the wild-type and MIC of the most resistant subpopulation (mutant prevention concentration, MPC) — is the zone where resistant mutants are preferentially selected. For aminoglycosides with high Cmax, concentrations transiently exceed the MPC, suppressing resistant mutant selection. For time-dependent beta-lactams, extended sub-MIC periods during the trough phase may lie within the MSW, potentially contributing to resistance selection — this is one argument for extended infusions that maintain concentrations above MIC throughout the interval.

Antibiotic class	PD class	PAE vs Gram-negatives	PAE vs Gram-positives	Dosing implication
Aminoglycosides	Concentration-dependent	2–7 h	2–4 h	Once-daily dosing (7 mg/kg q24h)
Fluoroquinolones	Concentration + time	2–6 h	1–4 h	Once-daily or twice-daily acceptable
Metronidazole	Concentration-dependent	2–4 h (anaerobes)	N/A	TDS or BD dosing validated
Beta-lactams	Time-dependent	0–2 h	2–4 h	Requires maintained T>MIC; extended infusion for resistant organisms
Vancomycin	AUC/MIC dependent	Minimal	1–3 h (S. aureus)	AUC 400–600 mg·h/L target; MIPD-guided
Azithromycin	AUC/MIC (tissue)	Extended (tissue PAE)	Extended (tissue PAE)	Enables 3–5 day short courses

Post-antibiotic effect

PAE by antibiotic class and organism

Frequently asked questions